Clinical Trials Logo

Respiratory Tract Diseases clinical trials

View clinical trials related to Respiratory Tract Diseases.

Filter by:

NCT ID: NCT06266442 Recruiting - Clinical trials for Respiratory Tract Diseases

M. Avium WGS During Mav-PD Treatment

Start date: February 2024
Phase:
Study type: Observational

This is a prospective observational study using whole genome sequencing (WGS) to investigate whether new strains (other than the initially identified strain(s)) of M. avium are responsible for persistently culture positive sputum during treatment (refractory disease), or the reversion to culture positive sputum after prior conversion to negative. The study will further investigate for differences between participants living in the Toronto/York region versus participants living elsewhere. The primary goal of this prospective observational study is to understand why some patients with M. avium lung disease have persistent or recurrent M. avium in their sputum despite treatment. The aim is to understand whether it is usually due to treatment failure or new infection.

NCT ID: NCT06252454 Recruiting - Dyspnea Clinical Trials

The Impact of Inhaled Furosemide and Perorally Administered Levodropropizine on Dyspnea in Patients With Respiratory Diseases

INFURO
Start date: February 27, 2024
Phase: Phase 2/Phase 3
Study type: Interventional

The goal of this monocentric double blinded cross over trial is to evaluate safety and tolerability of inhaled furosemide in patients with pulmonary diseases and dyspnea. The main question[s] it aims to answer are: - is inhaled furosemide safe and well tolerated? - is inhaled furosemide capable of dyspnea suppression and is there any additive effect of levodropropizine Participants will be given: - inhaled furosemide or placebo in double blinded cross over manner. Dyspnea severity and vital functions will be measured, adverse reactions monitored - all participants will receive levodropropizine open label. Dyspnea severity and vital functions will be measured, adverse reactions monitored

NCT ID: NCT06229886 Recruiting - Clinical trials for Tricuspid Regurgitation

Effect of PEEP on TRJV in Mechanically Intubated Pediatric Patients

Start date: December 6, 2023
Phase: N/A
Study type: Interventional

Prospective observational cohort study within the Pediatric Intensive Care Unit (PICU). We will perform point-of-care-ultrasound (POCUS) to quantify tricuspid regurgitant jet velocity (TRJV) on mechanically ventilated (MV) children. Mechanically ventilated (MV) children approaching extubation as per the discretion of the PICU clinical team will undergo a positive end expiratory pressure (PEEP) titration protocol in a safe and timely manner in the PICU. During this PEEP titration, POCUS will be performed by a pediatric intensivist and interpreted by a pediatric cardiologist. Medical demographics will be collected from the electronic medical record and recorded.

NCT ID: NCT06229613 Recruiting - Clinical trials for Respiratory Diseases

Exhaled Breath Aerosol for the Etiological Diagnosis of Respiratory Tract Infections: a Pilot Study

AEROPLEX
Start date: May 15, 2023
Phase:
Study type: Observational [Patient Registry]

Pilot study for the evaluation of the feasibility of pathogen detection in exhaled breath aerosols (XBAs) samples using the AveloCollect device. The aim of the study is to evaluate the feasibility of XBA collection and molecular detection of respiratory pathogens using the AveloCollect BlowTube device (index test) in subjects with a clinical presentation consistent with a respiratory infectious disease, compared to the same molecular assays performed on nasopharyngeal secretions (using commercially available swabs) and sputum (comparator tests).

NCT ID: NCT06229600 Recruiting - Respiratory Disease Clinical Trials

REspiratory reHABilitation and PSYchiatric Comorbidities

REHABPSY
Start date: January 2, 2024
Phase:
Study type: Observational

Patients with respiratory insufficiency, chronic obstructive pulmonary disease (COPD), pulmonary fibrosis, asthma, bronchiectasis, and, to a lesser extent, other pathologies that result in respiratory insufficiency and require rehabilitation are admitted to in-hospital Respiratory Rehabilitation. Several studies have assessed the impact of comorbidities in the most frequent respiratory diseases such as COPD, asthma, pulmonary fibrosis, and cystic fibrosis in terms of worsening mortality, morbidity, and disease progression. However, to our knowledge, there is no reliable quantification in Italy of the percentage of the presence of mental disorders (psychiatric/neurodegenerative) according to the Diagnostic and Statistical Manual Diploma in Social Medicine (DSM)-5 classification in respiratory patients as well as the prevalence of mental disorders present among patients requiring in-hospital rehabilitation programs. The study hypothesizes that these disorders are present among patients admitted to rehabilitation centers and that they may impact the final rehabilitation outcome.

NCT ID: NCT06227468 Recruiting - Healthy Clinical Trials

A Clinical Study to Map the HLA Genomic Region in the Greek Population

GENESIS
Start date: December 12, 2023
Phase:
Study type: Observational

The aim of GENESIS clinical study is to map the HLA genomic region in the Greek population and evaluate possible correlations with selected underlying diseases.

NCT ID: NCT06197646 Recruiting - Respiratory Disease Clinical Trials

Inhalation Therapy and Therapeutic Play

INHALATION
Start date: August 1, 2023
Phase: N/A
Study type: Interventional

The aim of this clinical research study was to determine the effect of the use of a cartoon character mask on treatment compliance and parental satisfaction and to evaluate the effectiveness of the cartoon character mask in children receiving inhaled therapy for the treatment of respiratory system diseases in children. The hypotheses it aims to answer are as follows: H1: Inhalers given using a mask with a cartoon character facilitate treatment compliance. H2: The inhaler given using a mask with a cartoon character makes treatment compliance difficult. H3: Inhaler treatment using a mask with a cartoon hero increases parental satisfaction. H4: Inhaler treatment using a mask with a cartoon hero decreases parental satisfaction. H5: Inhaler treatment using a mask with a cartoon hero has a positive effect on the hospitalization process. H6: Inhaler treatment using a mask with a cartoon hero has a positive effect on the recovery process. H7: Compared to routine inhaler mask use, the use of masks with cartoon heroes provides a positive relationship between treatment adherence and parental satisfaction. In the study, according to randomization, the intervention group will receive inhalers with masks, and the other group will receive inhalers routinely used in the clinic. The treatment of the children was planned by the physician, and no additional treatment was given for the study. Children's adherence to treatment and parents; satisfaction will be evaluated. The effectiveness of the masked inhaler used will be asked.

NCT ID: NCT06177925 Recruiting - Neoplasms Clinical Trials

A Phase Ⅱ Clinical Study of Adebrelimab Combined With Chemotherapy and Concurrent Radiotherapy for Extensive-Stage Oligometastatic SCLC

Start date: December 10, 2023
Phase: Phase 2
Study type: Interventional

This is an open-label, single arm Phase II study designed to evaluate the efficacy and safety of adebelizumab combined with carboplatin/Cisplatin plus (+) etoposide and concurrent radiotherapy in the first-line treatment of patients with extensive stage oligometastatic small cell lung cancer.

NCT ID: NCT06153485 Recruiting - Clinical trials for Chronic Respiratory Disease

Automated Titration for Home Oxygen Therapy

Start date: December 1, 2023
Phase: N/A
Study type: Interventional

Patients with chronic respiratory disease may be prescribed oxygen therapy. Currently, the dose of oxygen flow is fixed (FixedO2) depending on activity level i.e. rest, physical activity and sleep. Automated Titration of Oxygen (AutoO2) is a closed-loop system in which the oxygen flow to the patient is continuously machine adjusted to meet the patient's immediate needs on the basis of signals from pulse oximetry (SpO2). The purpose of this study is to examine if automated oxygen control based on pulse oximetry provided to participants is superior to prescribed fixed oxygen flow in keeping SpO2 within the intended target interval of 92 to 96% arterial oxygen saturation.

NCT ID: NCT06149494 Recruiting - Copd Clinical Trials

RCT of Vapendavir in Patients With COPD and Human Rhinovirus/Enterovirus Upper Respiratory Infection

Start date: November 20, 2023
Phase: Phase 2
Study type: Interventional

Vapendavir (VPV) is a drug being developed to treat human rhinovirus (RV) infection, one virus responsible for the common cold. Vapendavir prevents the virus from entering cells and making more infectious copies of itself. A study is being planned to investigate VPV in patients with chronic obstructive pulmonary disease (COPD, a lung disease making it difficult to breathe) who develop a rhinoviral infection; however, VPV has not been approved for use in treating any indication (disease) by the FDA or any other global regulatory agency. Therefore, VPV is considered investigational, and the study doctor is conducting this investigational research study. Safety will be monitored throughout the entire study.